Caris Life Sciences, Inc. Common Stock vs. Quest Diagnostics Inc.
CAI
Caris Life Sciences, Inc. Common Stock
$29.98 -3.04%
VS DGXQuest Diagnostics Inc.
$246.45 -0.40%
Quest Diagnostics Inc. (DGX) comes out ahead, leading on 6 of 11 compared factors.
Size & Scale
| CAI | DGX | |
|---|---|---|
| Market Cap | $8.74 billion | $27.31 billion |
| Revenue (TTM) | $989.61 million | $11.56 billion |
| Net Income (TTM) | $105.14 million | $1.11 billion |
DGX leads on 3 of 3 size & scale factors.
Valuation
| CAI | DGX | |
|---|---|---|
| P/E Ratio | 17.74 | 26.16 |
| Price / Book | 14.77 | 3.49 |
| Price / Sales | 8.83 | 2.36 |
DGX leads on 2 of 3 valuation factors.
Profitability
| CAI | DGX | |
|---|---|---|
| Net Margin | 10.62% | 9.63% |
| Return on Equity | 17.77% | 14.23% |
CAI leads on 2 of 2 profitability factors.
Dividend
| CAI | DGX | |
|---|---|---|
| Dividend Yield | 4.00% | 1.40% |
| Payout Ratio | 71.01 | 36.52 |
CAI and DGX split the dividend factors evenly.
Risk & Sentiment
| CAI | DGX | |
|---|---|---|
| Short Interest | 0.13% | 4.76% |
CAI leads on 1 of 1 risk & sentiment factors.
Dig deeper: CAI overview, CAI financials, DGX overview, DGX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.